key: cord-0785610-iajopejy
authors: Lugo Reyes, Saul O.; Condino-Neto, Antonio; Stepensky, Polina
title: Global perspectives on primary immune deficiency diseases
date: 2020-05-29
journal: Stiehm's Immune Deficiencies
DOI: 10.1016/b978-0-12-816768-7.00054-5
sha: b50376546f0a78bf88746cf39903be330a3898cc
doc_id: 785610
cord_uid: iajopejy

Poverty, mass migration, live vaccines, inbred marriage, exotic dishes, contaminated water, natural disasters and the next pandemic, they may all affect your patient with a congenital immune defect. In this chapter, we discuss some interesting aspects and regional differences in the field of Primary immune deficiencies: from climate change and emerging infectious diseases, to the geopolitics of gene discovery and blood trade, passing through consanguinity, founder effects, transfer factor, vaccination, medical curricula, and what the future may bring. We live on a changing, shrinking planet, and we believe we all need to know about customs, infections, and unique aspects in other regions of the world.

refugees living in unsanitary conditions, waiting near the borders indefinitely or walking for months, and zoonotic diseases might emerge from their close contact with animals while traversing forests or eating carcass meat. 5 To quote Rome's doctor Galen, ". when the entire year becomes wet or hot, there necessarily occurs a very great plague". 1 There are now approximately 400 single gene inborn errors of immunity (IEIs) underlying phenotypes as diverse as infection, malignancy, allergy, autoimmunity, and autoinflammation. 27 The global incidence of primary IEIs has been estimated to be 1:10,000 live births, although this is considered an underestimation due to limited patient access to diagnostic technologies and the challenges of diagnosing patients with atypical clinical presentations. Although IEIs are rare diseases from a global perspective, they are more prevalent in areas with highly consanguineous populations due to the predominance of autosomal recessive conditions. 28 AR forms, compared to X-linked (XL) or autosomal dominant forms, are clearly the most frequent, with more than 250 known AR IEI genes.

Generally, the high frequency of parental consanguinity and the occurrence of the disease in siblings of unaffected parents are highly suggestive of an AR mode of inheritance. This has resulted in a significant number of these AR IEI being first described in patients from highly consanguineous families. The rapid development of next-generation sequencing (NGS) during the last decade has driven the expeditious increase in the number of recognized disorders, which has led to few consequences. A majority of new inborn errors of immunity are initially described in a single family or a small number of kindreds 29, 30 .

Publications from a few countries with high rates of inbred marriages have demonstrated a specific distribution of diseases, with a predominance of severe forms such as combined immune deficiencies (CID) and phagocytic disorders, which is in contrast to the predominance of antibody deficiencies in other populations. Furthermore, consanguineous marriages have also been found to affect the types of genetic defects causing these diseases. 31 For example, deficiencies in major histocompatibility complex (MHC) class II and recombinase-activating gene (RAG) 1 or 2, which are transmitted in an AR pattern, are the most common causes of CID in the Middle East, whereas defects in the IL-2 common g chain, which are XL, are the most common cause of combined immune deficiencies in other parts of world. 32 Another example of differences in the genetic defects in consanguineous populations is chronic granulomatous disease (CGD). X-linked CGD represents approximately two-thirds of CGD patients in western countries, while AR forms of the disease appear to be the most common in regions with higher rates of consanguinity. 33e38 Immunodeficient patients with a history of parental consanguinity have been found to present with more severe PID phenotypes, as documented by the significant numbers of complications, atypical, severe and unusual infections, poor performance status, and a higher mortality rate. This could be due to an overrepresentation of more severe early-onset IEI in these populations. 39 The scientific value of studying monogenic disorders in consanguineous populations is high, and due to the recent availability of NGS technology, these diseases have been instrumental in the identification of novel and complex phenotypes associated with IEI. The identification of patients with unique clinical and immunologic manifestations within large consanguineous families may enable the recognition of novel disease-causing genes and contribute to the better understanding of immunological pathways and mechanisms.

The burden of IEI on an individual or country level necessitates strategic planning to mitigate their effects. In the MENA countries, the majority of patients have an AR mode of inheritance and come from families known to have the disease. Appropriate genetic counseling for affected families is an essential part of the management. In Saudi Arabia, Turkey, Iran, Israel, and Kuwait, genetic counseling, prenatal and preimplantation genetic diagnosis, and pre-marriage screening to identify carriers are offered to affected families. 40 Such services are costly and require sophisticated diagnostic facilities not available in most of the MENA countries.

Individuals at high risk of having a child with the inherited disease have limited options. They may opt to have no more children, which may compromise the family and break it apart. They also have the option to undergo prenatal diagnosis and, in the case of an affected fetus, termination of pregnancy can be offered, which is unacceptable in some societies due to national laws or traditional or religious issues. Undergoing pre-implantation genetic diagnosis (PGD) to have healthy children is another option. This option requires a collaborative team of immunologists, geneticists and genetic counselors, and the implementation of such interventions and access to genetic services may be limited due to geographic, religious, financial or social factors. 41 Most patients with IEI are asymptomatic at birth. Early diagnosis and appropriate treatment significantly improve the prognosis and outcome of the majority of these diseases. Severe combined immune deficiencies (SCID) have been recognized as candidates for population-based newborn screening (NBS) using the T cell receptor recombination excision circle assay (TREC) and found to be a cost-effective means to improve survival and reduce the morbidity of diagnosed children who undergo early hematopoietic stem-cell transplantation (HSCT). 42 The high disease incidence seen in regions with a high rate of consanguineous marriages is a critical driving force that would affect the incremental cost-effectiveness ratio. However, health authorities should recognize the importance of such a health problem and provide appropriate financial resources. Israel is the only MENA country performing universal SCID newborn screening. Recently published work showed an estimated incidence of SCID in Israel as high as 4.25:100,000 births, compared to w1.69-1.72:100,000 reported in countries with low rates of consanguineous marriages. 43 An NBS pilot study is ongoing in Saudi Arabia to identify the real incidence of SCID in the Saudi population. 38, 44 Early genetic diagnosis in patients originating from the same geographical area will help identify patients treatable by HSCT, which is often the only curative treatment, prior to the development of a severe clinical phenotype. Unfortunately, access to life-saving procedures in countries with a high rate of consanguinity and a burden of life-threatening IEI is often very limited.

Homo sapiens has proven to be an incredibly successful, rather invasive, species. Some 60,000 years ago, humans left East Africa in a series of migration waves that eventually covered all the planet. New Zealand and South America were the last corners of the globe to be populated. 45 This out-of-Africa worldwide expansion meant there was a series of small samples of founders from the original population with each successive radiating step or branch; that is, new populations were established by a small number of individuals from the previous, larger population. Each foundation meant a regional decrease in genetic diversity. 46 This decreased diversity, and the resulting perpetuation of a specific genetic variant from the founders, is what we know as the "founder effect". When most patients with a given IEI in a country or region have an identical variant, that disease may have propagated through that population by a founder effect. This is especially true in geographically confined or endogamic populations, such as the Native American, Amish, Ashkenazi Jews, or the Finnish. In the Czech Republic, the most common pathogenic variant for Nijmegen Breakage Syndrome, a founder homozygous 5bp deletion in NBN, can be found in 13% of newborns with microcephaly. 47 Another common explanation for identical variants in non-related patients, is the existence of mutation hotspots in a gene (eg., CFTR, DOCK8), or the existence of a pseudogene (eg., NCF1), that favor large genomic deletions or DNA polymerase errors. Founder effects have been described for several IEI. The disclosed patterns of founder mutations are twofold: those that are shared with other inbred populations, and those that are specific to some geographic regions. One of the most illustrative examples for a regional founder effect is the AR MHC class II combined immunodeficiency that has been considered to be a "North-African disease." The original study from Tunisia revealed a founder effect for the highly frequent c.338-25_338del26 mutation (also known as 752delG-25) in the RFXANK gene, a 26-bp deletion. The founder event causing this mutation is estimated to have happened approximately 2250 years ago, a period concurrent to the Berber civilization. This is consistent with previous reports showing that the population of North Africa, particularly in Tunisia, Algeria, and Morocco has a common genetic background, and that founder mutations could be shared in some of these countries. 48, 49 Another recurrent mutation is in VPS45 (c.671 C > A; p.T224A.) which has been identified in 12 Palestinian patients from unrelated families with primary myelofibrosis of infancy; this description was limited to patients originating from Palestine, thus suggesting a possible founder effect for this variant. 50 Furthermore, a recent study reported the recurrence of the same homozygous nonsense mutation (Q289X) in CARD9 in eight Algerian and four Tunisian patients from seven unrelated families with deep dermatophytosis. This finding was due to a founder effect with the common ancestor living approximately 975 years ago. Additional deleterious founder variants have been reported in consanguineous populations as the underlying cause of a large spectrum of monogenic AR diseases. 51, 52 The clinical implications of the existence of founder effects in a given population include the implementation of preventive approaches through genetic counseling and prenatal diagnosis in affected families. Whole exome sequencing (WES) interpretation should incorporate known regional founder effects as well as variants identified in unique populations.

Deleterious variants are enriched in genomic regions or "runs" of homozygosity found in populations with a high rate of identity-by-descent. Historical bottlenecks and geographical isolation, together with the foundation events, have resulted in relatively recent inbreeding in populations of Latin America. 53 In all the world, there are few true genetic isolates. Latin America has a unique admixture of parental Native American, Iberian and West African populations. Population migration, foundational histories, and sometimes a small population size in a confined space, have resulted in regional differences.

The Central valley of Costa Rica, with one of the highest prevalences of Ataxia-Telangiectasia (AT 3:100,000) is considered to have a high rate of inbreeding, 54 and 4 founder effect variants in the ATM gene account for 76% of patients. 55, 56 Similarly, there seems to be a high prevalence of SCID, and at least two founder effects for Hermansky-Pudlak syndrome in North-West and Central Puerto Rico. 57 In Mexico, there are hundreds of small, closed populations of less than 1000 inhabitants, where tradition and seclusion account for a high rate of inbreeding; founder effects may account for a high prevalence of AT and Griscelli syndromes in Mexican patients. 58 Argentina has the largest share of European descent in the region: 97.2%, with about 63% of Italian ancestry. 59 Their prevalence of IEI are thus probably more in accord with what has been reported in European and Anglo-Saxon populations. Notably, ever since its inception, the LASID registry has many more patients from Argentina 60e62 ; this is, undoubtedly, a testament to their astute clinicians and researchers, but it may also reflect a higher prevalence of IEI in that country.

Even polygenic conditions exhibit regional variation in prevalence. A case in point, Selective IgA deficiency (SIgAd) has been reported to be as frequent as 1:500 in healthy adult blood donors from Caucasian populations 63 in the USA, Europe, Australia and Iran, ranging from 1:300 to 1:3000 (e.g., 1:250 in Lithuanian schoolchildren 64 ; 1:651 in adults from Iran 65 ). A group in Brazil found the prevalence of SIgAd to be 1:1000, 66 while in China (1:5000), Japan (1:18,500) and India (none) it is far less prevalent. 67e69 SIgAd is seldom seen in Mexico.

Similarly, the share of antibody defects within the pie chart of all defects has been reported at between 25 and 33% (the Middle-East) and 77% (Australia and New Zealand), depending on the country or registry. 70e76 Consanguinity and the proportion of European descent are thought to determine the prevalence.

Although the Bacille Calmette-Guérin (BCG) vaccine, containing live attenuated Mycobacterium bovis bacilli, has been proscribed in several countries, it is still mandatory at birth in most of the world, 77 especially in those countries where tuberculosis is endemic (http://www.bcgatlas.org). This is a challenge for the immune systems of newborn children whose immune competence is unknown; infants with T cell or phagocyte inborn errors develop adverse reactions to BCG (local or regional "BCG-itis" or disseminated "BCG-osis"). 78 The vaccine-associated disease for SCID is around 40%e50%, while that for chronic granulomatous disease (CGD) is 25%e30%. 79 This is often the first manifestation of disease, as BCG is usually administered before the immune deficient patients have had a chance to encounter other infectious agents. In effect, then, BCG adverse reactions behave as a screening or challenge test in many countries, and IEI should be suspected and ruled out in such affected patients, while formally proscribed in their siblings. As a screening tool, however, it is too dangerous, and immunologists should advocate for a delayed application of the vaccine, 80 starting perhaps at 6 months, when families and clinicians have had a chance to notice or test for anomalies in their patients' immune system.

The oral Polio vaccine (OPV, Sabin) should not be given to children with combined or antibody deficiencies, as it may cause flaccid paralysis or meningoencephalitis. 81 Not only that, but patients with immune deficiency can show a delayed clearance of the virus and may act as reservoirs 82 allowing for the virus to stay longer, reseed and mutate within a population.

Any immunosuppressed, and some IEI patients with specific monogenic or digenic defects may develop overwhelming infection after varicella-zoster 83,84 (GATA2, DOCK2, DOCK8, TYK2, IFNGR1, POL3A, POL3C) or the measles-mumpsrubella (IFNAR1, IFNGR2, IFNAR2 deficiencies) vaccines, 85, 86 despite the vaccines' otherwise excellent safety profiles. Any indication of immune incompetence, including failure to thrive or recurrent hospitalization, 83 should alert the provider, who must also always monitor for adverse reactions after vaccination.

Children with severe IEI rely on herd immunity to avoid exposure to infectious agents that are preventable by vaccination. 87 Even the concentration of specific antibodies in a given IVIG batch will depend on the donors' collective immunity. As vaccination rates drop in Europe and the USA, more patients will be at risk of overwhelming infections.

Chronic granulomatous disease (CGD)

Most patients (60%e80%) are X-linked (gp91 phox deficient) globally, except in the MENA region, where the proportion is inverted (>60% AR disease) due to the high rate of consanguinity. 76 Very few CGD patients in the USA suffer from mycobacterial infections, 88 but in countries where tuberculosis is endemic and the BCG vaccine is mandatory, susceptibility to mycobacteria is well documented. 79 Children with CGD are more likely to present with Amebic liver abscess in regions endemic for this protozoan parasite and with poor sanitary conditions. CGD patients inhale Aspergillus spores from organic dust found in compost piles, straw and leaves in garden, forest and farm settings, but also from construction sites. 89 No amount of interferon or antifungal prophylaxis seems to suffice to keep adolescents entirely safe from pulmonary invasive aspergillosis, 90 thus, education on the risks is useful. The current trend toward organic farming may also represent an exposure risk for them. 91 Recombinant subcutaneous interferon gamma (IFNG) is much more used in America 88 than in Europe to treat CGD. 92 In the US and Mexico, 75%e80% of CGD patients receive IFNG three times a week, 58 while in Europe only around 33% are also treated with it, while most patients seem to do well under antimicrobial prophylaxis alone. 92, 93 IFNG was introduced in the 1980s, before the physiopathology of CGD was entirely clear, in the hope of boosting the patients' phagocytes ability to destroy their intracellular prey. 94 There is one large, multi-centric, well-conducted randomized clinical trial from 1991, 95 that demonstrated a greater than 60% reduction of serious infections in patients treated with IFNG. However, there are some smaller cohorts or anecdotal reports that point to a smaller effect size and to some adverse effects. 93,96e98 More recently, Condino-Neto and colleagues in Sao Paulo 99 reported that IFNG improves the splicing efficiency of CYBB, and thus it might be especially (or exclusively) useful in patients with X-linked CGD bearing splice-site variants.

IFNG is, in fact, found increased in the serum of CGD patients, and the prolonged administration of this inflammatory cytokine may, at least theoretically, result in increased propensity to hemophagocytic lymphohistiocytosis (HLH) or systemic autoimmunity, two inflammatory complications that have been repeatedly documented in CGD. 100e104 Interestingly, autoimmune complications in CGD patients seem to be more common in the USA 88, 101 and Mexico (around 25%) than in Europe (6%), 92 where they are no more frequent than in the general population (5%).

In Western cohorts, CD40LG is the most prevalent genetic etiology of HIGM, making up nearly 65e70% of all cases and resulting in a more severe form of the disease. 105 Similar to CGD, however, the majority of HIGM patients from MENA countries will have the AR forms of the disease (mainly AICDA and CD40). 106 HIGM syndrome has a wide clinical presentation that includes respiratory tract infections, autoimmune phenomena, and a wide range of opportunistic infectious agents. Case series from Brazil and Latin America 107 have found a high incidence of fungal infections, including Aspergillus, Candida, and Paracoccidioides, in addition to Pneumocystis jirovecii. Fungal infections affect over 85% of CD40L deficiency cases in South America. Tuberculosis, BCG reactions, Isospora belli, and Leishmania infections have also been reported in this patient group. 108

Nearly all plasma donor centers and gammaglobulin manufacturing facilities are located in the USA and Europe. The concentrations of specific antibodies will depend on the collective immune experience of the donor pool, and those specific antibodies may make a difference on patients with antibody deficiencies under replacement therapy. 109 Increased awareness has brought an increase of diagnoses of IEI. In Latin America, the prescriptions of immunoglobulins have increased over 130% in the last decade, following outreach and educational programs run by the Latin American Society for Primary Immunodeficiencies (LASID) throughout the continent, and the establishment of Jeffrey Modell diagnostic centers in strategic geographical areas. 110 Regional centers of plasma donors are desirable in order to increase the diversity of available antibodies in parenteral immunoglobulin preparations. It seems urgent to discuss and approve laws that allow and regulate plasma collection locally, to avoid the dependence on imported products that do not contain the immunologic experience of the population, including antibodies against tropical pathogens. The ethics around the process of donation and shipping of blood, however, must be strictly regulated and supervised, as plasma companies in the past have been known to abuse prison inmates, undernourished Haitians and skid row donors, 111, 112 and the blood trade played a considerable role in the HIV and HCV pandemics. 112, 113 Hematopoietic stem-cell transplantation (HSCT) and donor registries Treatment guidelines and conditioning regimes for HSCT are fairly standardized worldwide. 114 What decides prognosis and survival then, is the availability of resources and each center's learning curve. Two crucial aspects are the donation culture and donor registries in a given country. When a patient who needs an HSCT cannot find an HLA-compatible donor within his or her family, the probability of finding a matched unrelated donor is higher with donors of their same ethnic background. 115 Moreover, the quest for an unrelated donor might entail graft shipment from abroad, with which waiting times more than double and the total costs skyrocket. Absence of local registries and underdevelopment of accredited stem cell transplantation programs in developing countries can significantly influence and compromise the chances for cure by HSCT.

In Latin America and Asia, some lesser-known and poorly understood immune modulators are still in use to treat patients with IEI, the most famous of which is Transfer factor (TF). TF, or leukocyte dialysate, is obtained from donor peripheral blood mononuclear cells, mostly lymphocytes, when they are lysed and forced through a semi-permeable membrane that allows only particles between 3.5 and 12 kDa to go through 116 ; the resulting dialysate consists of oligopeptides from lymphocytes. Developed in 1955 by Dr. H.S. Lawrence in Rutgers University, TF was thus named because of its observed ability to transfer immunity, or the delayed skin response to tuberculin, from one patient who recovered from tuberculosis to a Tb-naïve volunteer. 117 The pioneers of clinical immunology, including Robert Good, Richard Gatti and Claude Griscelli (and Renato Berron in Mexico) used TF to treat patients from the 1960s to the 1980s, 118e120 and some progress was made at elucidating TF's mechanism of action and molecular nature (see for example, Dr. Charles H Kirkpatrick's work 121e123 ). Yet, following the 1980s HIV pandemic, and facing stricter regulations from the FDA, TF was mostly forgotten outside of a few countries such as Cuba, Mexico, Italy and China, where it is still alive and kicking. 124e126 Today, there even are TF copycats that include bovine colostrum and crocodile transfer factors, which are sold in the streets and as part of get-rich-quick schemes over the internet; TF is promoted by believers: patients, relatives, well-intended clinicians and charlatans alike, and it is supposed to be good for nearly everything immunological: from allergies to cancer, all the way through autoimmunity, infections or IEI.

Other than its proteinaceous or oligopeptidic nature, it is generally accepted that TF is antigen-specific, capable of inducing the release of IFNG and a Th1 response. 123, 127, 128 In the immunodeficient patient, it is sometimes used to treat chronic intracellular infections, such as laryngeal papillomata or mucocutaneous fungi, always as adjuvant therapy, 129 since its observed effect is modest at best.

TF research fell into oblivion in the US as the result of two events: the onset of the HIV epidemic, with the concern of transmitting the virus through human cell preparations, 127, 130, 131 and the FDA decision not to allow clinical trials with unidentified molecules. Mass spectrometry, high-performance liquid chromatography and peptide sequencing are some of the techniques that could be applied to learn more about the structure and mechanism of action of TF.

Autosomal recessive variants will continue to be discovered in patients from the MENA and South India, due to the high rate of consanguinity and births in the region. However, the encounters of patients with microorganisms, and the conditions in which they coincide, will determine their clinical presentation around the globe.

Biological diversity is greater around the equator, where the Earth receives more heat. Susceptibility to tropical infectious diseases, including parasites transmitted by vectors, will manifest themselves in patients from these latitudes, or in those returning from travels to the tropics. This, of course, will change gradually, as parasites and other life forms move toward the poles, increasingly more temperate, complicating the epidemiological landscape. 132 In addition to changes related to global warming, there can be infections that erupt abruptly, as evidenced by the SARS and MERS coronaviruses, HIV, Zika, Chikungunya and Ebola during the last four decades. 1 Viruses and other microorganisms are continuously evolving through spillover from other species, 113 mutating to adapt to their new hosts, subject to their own genetic bottlenecks and founding events. 133 A few examples of recognized threats to patients are given: l Tick-borne viral encephalitis (TBE), dengue fever, zika virus, entamoeba encephalitis, visceral leishmaniasis, trypanosomiasis, avian flu, chikungunya, may all affect patients with hypogammaglobulinemia, innate immune defects, or T-cell deficiencies. 5 l Viral hepatitis currently affects over 400 million people worldwide, in a silent pandemic that is expected to peak, bringing a tragic toll of disability and death by cirrhosis, liver failure and cancer. Patients with innate immune, antibody and cellular defects, all have increased susceptibility to viruses and are at risk of acquiring Hep B and/or C viruses. l Gastrointestinal infections caused by intracellular Gram-negative bacteria, such as Salmonella and Shigella (including dysentery and typhoid fever) are more prevalent in places with poor sanitation and high temperatures during the summer. l Malaria has been called the ultimate ecological disease. 1 Both the parasite (plasmodium) and the vector (the female Anopheles mosquitoes) thrive in wet, warm settings with stagnant water, such as settings seen with deforestation, floods and poverty in Africa, the tropics or around the Mediterranean basin today, where Malaria causes over one million deaths of children every year, mostly during the fall. l Another killer of at least one million humans every year, tuberculosis is transmitted by droplets in close contact. Mycobacteria love dense cities, dirt and squalor. 1 Patients with MSMD or CGD might be affected by urbanization, overpopulation and impoverishment in a globalized world. l Turtle pets are known to carry salmonella. Turtles and other reptiles (lizards, snakes, geckos, dragons) are becoming increasingly popular as choice of pets. 134 l Foodborne and waterborne parasites, including the cysticercosis-causing Taenia solium, or the sclerosing cholangitiscausing Cryptosporidium parvum, will infect patients living in, or returning from, countries with unsanitary conditions. Primary sclerosing cholangitis, caused by waterborne protozoa (cryptosporidium and microsporidia), can greatly complicate the prognoses of children with combined immune deficiencies. Contaminated water and dog saliva harbor these parasites. l Dishes that include raw animals (fish, rodents, frog, snake), undercooked meat or poorly prepared salads, may result in exotic infections such as those caused by Yersinia pestis, 135,136 roundworms or hookworms. 137

Infections with a regional distribution can represent a diagnostic clue to an IEI. This section lists several emerging infections and the immune deficiencies with unique susceptibilities.

Tick-borne viral encephalitis (TBE), Dengue fever, Zika virus, Entamoeba encephalitis, visceral leishmaniasis, trypanosomiasis, avian flu, Chikungunya, may all affect patients with hypogammaglobulinemia, innate immune defects, or T cell deficiencies. 5 Most tick-borne diseases are more severe in the elderly. Although few cases in immune deficient individuals have been reported, they likely represent hosts with altered manifestations.

Hydroa vacciniforme-like lymphoproliferative (HVLL) disease is a curious disorder of childhood endemic to Japan, Peru, Bolivia, Guatemala and a couple of states in Mexico, where it is also known as Ruiz-Maldonado's disease. It involves cutaneous hyper-sensitivity to UV-light (and/or mosquito bites) with disfiguring ulcers and scars, Epstein-Barr virus (EBV) chronic latent infection, and T cell cutaneous lymphoma. 138 While many patients follow an indolent chronic course, some may develop systemic lymphoma with T cell or NK cell monoclonal proliferation. In addition to having a susceptibility to EBV and cancer, with a seemingly demonstrable hematopoietic cell phenotype, 139 HVLL has been reported in a patient with GATA2 haploinsufficiency and hemophagocytic lymphohistiocytosis (HLH). 140 Similarly, endemic mycosis caused by dimorphic fungi (Histoplasma, Coccidioides, Paracoccidioides, Blastomyces, Sporothrix, Penicillium and Emmonsia spp.), when they cause invasive or disfiguring infections, have been associated with interferon gamma immunity defects, autoantibodies to IFN-g or CARD9 deficiency. 141 Patients and their families from regions endemic to certain infections depend on their clinicians' suspicion, diligence and thoroughness to find an explanation for their susceptibility. When all else fails, next generation sequencing for unknown pathogens and WES may help identify monogenic causes and delineate genetic susceptibility to unusual infections.

In the United States, TREC newborn screening programs for SCID are mandated. When an asymptomatic infant with combined immune deficiency is detected, he or she may undergo a targeted exome sequencing and HSCT during the following months, thus achieving a correct genetic diagnosis and curative treatment before his/her first serious infection.

In stark contrast, SCID patients in the developing world are still weeded-out by natural selection. Underdiagnoses, diagnostic delay, prohibitive costs and high lethality are the rule. The cost of the TREC assay can reach up to 2e3 times higher after custom duties are applied on imported reactants and material.

To make matters worse, low-income countries must deal with very low ratios of physicians per 1000 people; side jobs for health practitioners with a public-private overlap; and the "brain drain" of trained scientists and doctors who leave for a better paid job in industrialized countries. A healthcare system with scarce, exhausted or distracted physicians and researchers will underserve patients.

There is an ongoing race for gene discovery. The most influential groups in the field (mostly in Europe and the USA) lead this race, as they were able to position themselves as international referral centers for patient samples from all around the globe. Those same centers with state-of-the-art technology and high-impact novel reports, will get most of the available grants and resources globally. To such giants, the rest of the world send their graduates and samples, in effect saturating the system when we all "go for the blonde". Regional networks with specialized laboratories by country with cooperative collaborations, would surely work best in the long run for all the research centers involved.

Right now, it is not clear who will win the war between humans and bacteria. If superbugs prevail over antibiotics, gain-offunction variants and dysregulation disorders of the immune system that result in an exaggerated inflammatory response against infection, may confer a survival advantage for children in the next century, as they presumably did before the advent of antibiotics. 142 Loss-of-function variants may also be selected. 700 years ago, the bearers of the CCR5-delta32 deletion survived a smallpox epidemic in Europe, 143 and today their homozygous descendants are elite survivors of the HIV infection 144 ; one of the unpredictable outcomes of millennia-long, ongoing experiments of nature, and of the evolution of the immune system. Sexual reproduction, through the random crossover of genetic material from our ancestors, and the imperfect replication of DNA, guarantees that at least some members of our species will survive the next pandemics.

Regarding medical students, residents and fellows in training, programs that include basic and clinical immunology, and those that cover microbiology, molecular biology, genetics, bioinformatics and hematology, are better suited to prepare trainees who will be able to recognize, diagnose and treat patients with IEI, as opposed to curricula with an undue emphasis on allergic diseases.

Eventually, the function of every gene in the human genome will be known, and all or most of the variants will have been categorized. We will better understand digenic and polygenic diseases and unravel the influence of the microbiome and epigenetic mechanisms. Sooner or later the cost of sequencing the entire genome will come down to less than 25 USD, all children will have their genomes sequenced at birth, and researchers by then will have acquired the algorithms and computational power to automatically process, map, filter, annotate and analyze all relevant variants, perhaps in a handheld device.

Many of our current regional differences, and of our diagnostic efforts will have become irrelevant, obsolete then, but in the meantime, there is still much work to do. After all, we are in the business of fighting off natural selection by protecting our patients, the most vulnerable members of the pack; and for that, we need to keep an eye on their weaknesses and their predators, the trillions of microbes with whom we share the planet.

The fate of Rome: climate, disease, and the end of an Empire

Intergovernmental Panel on Climate Change

Emerging vector-borne diseases in a changing environment

How the world's first dengue vaccination drive ended in disaster -scientific American

Emerging infections and pertinent infections related to travel for patients with primary immunodeficiencies

Consanguineous marriages: preconception consultation in primary health care settings

Consanguinity and its relevance to clinical genetics

It's ok, we're not cousins by blood": the cousin marriage controversy in historical perspective

Consanguineous marriages in Jordan: why is the rate changing with time?

Consanguinity and genetic diseases in North Africa and immigrants to Europe

Quantification of homozygosity in consanguineous individuals with autosomal recessive disease

The consequences of consanguinity on the rates of malformations and major medical conditions at birth and in early childhood in inbred populations

Consanguinity and its relevance to clinical genetics

Consanguineous marriage in Jordan

Reproductive behavior and health in consanguineous marriages

Inbreeding and congenital heart diseases in a north Indian population

Consanguineous marriages in Beirut: time trends, spatial distribution

Characteristics of genetic diseases in consanguineous populations in the genomic era: lessons from Arab communities in North Israel

Consanguinity in Lebanon: prevalence, distribution and determinants

Consanguinity trends and correlates in the Palestinian Territories

Genetic testing and genomic analysis: a debate on ethical, social and legal issues in the Arab world with a focus on Qatar

Consanguinity and reproductive health among Arabs. Reprod Health

Consanguineous marriage in Jordan: an update

Close inbreeding and low genetic diversity in Inner Asian human populations despite geographical exogamy

Genetic disorders among Palestinian Arabs. 4: genetic clinics in the community

Decrease in consanguinity among parents of children born in Norway to women of Pakistani origin: a registry-based study

International union of immunological societies: 2017 primary immunodeficiency diseases committee report on inborn errors of immunity

Comprehensive genetic results for primary immunodeficiency disorders in a highly consanguineous population. Front Immunol

Guidelines for genetic studies in single patients: lessons from primary immunodeficiencies

Unbiased targeted next-generation sequencing molecular approach for primary immunodeficiency diseases

Patterns of primary immunodeficiency disorders among a highly consanguineous population: cairo university pediatric hospital's 5-year experience

Phenotypical heterogeneity in RAG-deficient patients from a highly consanguineous population

Clinical, functional, and genetic characterization of chronic granulomatous disease in 89 Turkish patients

Combined immunodeficiency: the Middle East experience

Consanguinity in primary immunodeficiency disorders; the report from Iranian primary immunodeficiency registry

Consanguinity and primary immunodeficiencies

Thirty years of primary immunodeficiencies in Turkey

Primary immunodeficiency diseases in highly consanguineous populations from Middle East and North Africa: epidemiology, diagnosis, and care. Front Immunol

Lessons from genetic studies of primary immunodeficiencies in a highly consanguineous population. Front Immunol

Science and society: genetic counselling and customary consanguineous marriage

Genetic counseling in southern Iran: consanguinity and reason for referral

Newborn sequencing in genomic medicine and public health

First year of Israeli newborn screening for severe combined immunodeficiency-clinical achievements and insights. Front Immunol

High incidence of severe combined immunodeficiency disease in Saudi Arabia detected through combined T cell receptor excision circle and next generation sequencing of newborn dried blood spots. Front Immunol

Brief history of everyone who ever lived: the stories in our genes. Weidenfeld & Nicolson

Cavalli-sforza LL. A serial founder effect model for human settlement out of Africa

Nijmegen breakage syndrome in 13% of age-matched Czech children with primary microcephaly

The 752delG26 mutation in the RFXANK gene associated with major histocompatibility complex class II deficiency: evidence for a founder effect in the Moroccan population

Clinical, immunological and genetic findings of a large tunisian series of major histocompatibility complex class II deficiency patients

How we approach: severe congenital neutropenia and myelofibrosis due to mutations in VPS45. Pediatr Blood Cancer

Report of the Tunisian registry of primary immunodeficiencies: 25-years of experience

Deep dermatophytosis and inherited CARD9 deficiency

Understanding the hidden complexity of

Is the Central valley of Costa Rica a genetic isolate?

Ataxia-telangiectasia: identification and detection of founder-effect mutations in the ATM gene in ethnic populations

A model for ATM heterozygote identification in a large population: four founder-effect ATM mutations identify most of Costa Rican patients with ataxia telangiectasia

Mutation of a new gene causes a unique form of HermanskyePudlak syndrome in a genetic isolate of central Puerto Rico

Clinical features, noninfectious manifestations and survival analysis of 161 children with primary immunodeficiency in Mexico: a single center experience over two decades

Inferring continental ancestry of argentineans from autosomal, Ychromosomal and mitochondrial DNA

Primary immunodeficiency diseases in Latin America: proceedings of the second Latin American society for immunodeficiencies (LASID) advisory board

Latin American challenges with the diagnosis and treatment of primary immunodeficiency diseases

Primary immunodeficiency diseases in Latin America: the second report of the LAGID Registry

Selective IgA deficiency

Population-based screening for selective immunoglobulin A (IgA) deficiency in Lithuanian children using a rapid antibody-based fingertip test

Selective immunoglobulin A deficiency in Iranian blood donors: prevalence, laboratory and clinical findings

Frequency of selective IgA deficiency among Brazilian blood donors and healthy pregnant women

Prevalence of immunoglobulin A deficiency in Chinese blood donors and evaluation of anaphylactic transfusion reaction risk

Selective IgA deficiency in Japanese blood donors: frequency and statistical analysis

Low prevalence of IgA deficiency in north Indian population

From genotype to phenotype. Further studies measuring the impact of a Physician Education and Public Awareness Campaign on early diagnosis and management of primary immunodeficiencies

Primary immunodeficiency disorders in Kuwait: first report from Kuwait national primary immunodeficiency registry

The French national registry of primary immunodeficiency diseases

Primary immunodeficiency in Iran ;: first report of the national registry of PI

Primary immunodeficiency diseases: a 30-year patient registry from the referral center for primary immunodeficiencies in Greece

Primary immunodeficiencies in Switzerland: first report of the national registry in adults and children

Frequency and clinical manifestations of patients with primary immunodeficiency disorders in Iran: update from the Iranian primary immunodeficiency registry

The BCG world atlas: a database of global BCG vaccination policies and practices

Immunological conditions of children with BCG disseminated infection

Mycobacterial disease in patients with chronic granulomatous disease: a retrospective analysis of 71 cases

BCG vaccination in patients with severe combined immunodeficiency: complications, risks, and vaccination policies

Poliovirus excretion following vaccination with live poliovirus vaccine in patients with primary immunodeficiency disorders: clinicians' perspectives in the endgame plan for polio eradication

Patients with primary immunodeficiencies are a reservoir of poliovirus and a risk to polio eradication

Fatal varicella due to the vaccine-strain varicella-zoster virus

Inborn errors in RNA polymerase III underlie severe varicella zoster virus infections

A digenic human immunodeficiency characterized by IFNAR1 and IFNGR2 mutations

Human IFNAR2 deficiency: lessons for antiviral immunity

Herd immunity and primary immune deficiencies

Report on a national registry of 368 patients

Fulminant mulch pneumonitis: an emergency presentation of chronic granulomatous disease

Invasive aspergillosis in chronic granulomatous disease

Improvement of crop yield by phosphate-solubilizing Aspergillus species in organic farming

Chronic Granulomatous disease: the European experience

Interferon gamma for Chronic granulomatous disease

Chronic Granulomatous Disease; fundamental stages in our understanding of CGD

A controlled trial of interferon gamma to prevent infection in Chronic granulomatous disease

Long-term outcome of patients with p22 phox -deficient chronic granulomatous disease on Jeju Island

Recombinant gamma interferon and autoimmune thyroid disease

Corticosteroid therapy reversed progressive chronic granulomatous lung disease following deterioration on interferon-gamma treatment

Interferon-gamma improves splicing efficiency of CYBB gene transcripts in an interferonresponsive variant of chronic granulomatous disease due to a splice site consensus region mutation

Development of systemic lupus erythematosus in a young child affected with chronic granulomatous disease following withdrawal of treatment with interferon-gamma

Chronic granulomatous disease as a risk factor for autoimmune disease

Impaired phagocytosis of apoptotic cells by macrophages in chronic granulomatous disease is reversed by IFN-g in a nitric oxide-dependent manner

Visceral leishmaniasis associated hemophagocytic syndrome in patients with chronic granulomatous disease

Hemophagocytic lymphohistiocytosis in children with chronic granulomatous disease

Update on the hyper immunoglobulin M syndromes

Novel and recurrent AID mutations underlie prevalent autosomal recessive form of HIGM in consanguineous patients

First report of the hyper-IgM syndrome registry of the Latin American society for immunodeficiencies: novel mutations, unique infections, and outcomes

Expanding the clinical and genetic spectrum of human CD40L deficiency: the occurrence of paracoccidioidomycosis and other unusual infections in Brazilian patients

Analysis of specific IgG titers against tick-borne encephalitis in patients with primary antibody deficiency under immunoglobulin substitution therapy: impact of plasma donor origin

Global report on primary immunodeficiencies: 2018 update from the Jeffrey Modell Centers Network on disease classification, regional trends, treatment modalities, and physician reported outcomes

The Big Business of Blood Plasma d $2 a Day

Nine pints : a journey through the money, medicine, and mysteries of blood

Spillover: animal infections and the next human pandemic

European society for immunodeficiencies. EBMT/ESID guidelines for haematopoietic stem cell transplantation for primary immunodeficiencies

Hematopoietic Cell Transplant Therapy & Donor Matching

Army Medical Research Institute of Infectious Diseases, National Institute of Allergy and Infectious Diseases

Transfer Factor -current status and future prospects

Transfer factor therapy in immuno-deficiencies

Wiskott-Aldrich syndrome, a genetically determined cellular immunologic deficiency: clinical and laboratory responses to therapy with transfer factor

Report of a patient with T-cell deficiency and normal B-cell function: a new immunodeficiency disease with response to transfer factor

Therapeutic potential of transfer factor

Transfer factors: identification of conserved sequences in transfer factor molecules

Profiles of cytokine production in recipients of transfer factors

The transfusion medicine program in Cuba

Indications, usage, and dosage of the transfer factor

Efficacy of transfer factor in treating patients with recurrent ocular herpes infections

Non-induced leukocyte extract reduces HIV replication and TNF secretion

Transfer factor and allergy

Transfer factor: an overlooked potential for the prevention and treatment of infectious diseases

AIDS and transfer factor: myths, certainties and realities

Transfer factor in the era of AIDS

Impact of climate change in the epidemiology of vector-borne diseases in domestic carnivores

Sequential bottlenecks drive viral evolution in early acute hepatitis C virus infection

Reptiles now more popular pets than dogs -Telegraph

Couple dies of the plague after eating raw marmot meat: reports. People

A 12-case outbreak of pharyngeal plague following the consumption of camel meat

The woman with a worm in her head : and other true stories of infectious diseases. First edit

Cutaneous EBV-related lymphoproliferative disorders

Platelets in Tissue Repair: control of apoptosis and interactions with regenerative cells

Association of GATA2 deficiency with severe primary Epstein-Barr virus (ebv) infection and ebv-Associated cancers

Cellular and molecular defects underlying invasive fungal infections-revelations from endemic mycoses

Survival of the sickest : a medical maverick discovers why we need disease. William Morrow

The evolutionary history of the CCR5-D32 HIV-resistance mutation

The geographic spread of the CCR5 D32 HIV-resistance allele